RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Needham & Company Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold
April 28, 2014 1:46 PM EDTNeedham & Company downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Strong Buy to Hold with a price target of $14.00.
Analyst Chad Messer comments, "OncoGenex reported negative top line data from the pivotal SYNERGY trial testing custersin on top of 1st line chemotherapy with docetaxel in patients... More
OncoGenex Pharmaceuticals (OGXI), Teva (TEVA) Said Phase III SYNERGY Trial Did Not Meet Primary Endpoint
April 28, 2014 7:05 AM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) and OncoGenex Pharmaceuticals, Inc.(NASDAQ: OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone... More
